Efficacy and Safety of Alemtuzumab in Patients With RRMS Is Durable Over 10 Years: Follow-up From the CAMMS223 StudyKrzysztof W. Selmaj,Mario Habek,Ann Bass,David Brassat,Vesna Brinar,Alasdair J. Coles,Anton Vladic,Sibyl E. Wray,David H. Margolin,Karthinathan Thangavelu,Madalina Chirieac,Linda Kasten,Edward J. FoxMULTIPLE SCLEROSIS JOURNAL(2017)引用 0|浏览6暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要